Cite
Mepolizumab decreases tissue eosinophils while increasing type‐2 cytokines in eosinophilic chronic rhinosinusitis.
MLA
Walter, Sophie, et al. “Mepolizumab Decreases Tissue Eosinophils While Increasing Type‐2 Cytokines in Eosinophilic Chronic Rhinosinusitis.” Clinical & Experimental Allergy, vol. 52, no. 12, Dec. 2022, pp. 1403–13. EBSCOhost, https://doi.org/10.1111/cea.14152.
APA
Walter, S., Ho, J., Alvarado, R., Smith, G., Croucher, D. R., Liang, S., Grayson, J. W., Mangussi, G. J., Van Es, S. L., Earls, P., Rimmer, J., Campbell, R., Kalish, L., Sacks, R., & Harvey, R. J. (2022). Mepolizumab decreases tissue eosinophils while increasing type‐2 cytokines in eosinophilic chronic rhinosinusitis. Clinical & Experimental Allergy, 52(12), 1403–1413. https://doi.org/10.1111/cea.14152
Chicago
Walter, Sophie, Jacqueline Ho, Raquel Alvarado, Greg Smith, David R. Croucher, Sharron Liang, Jessica W. Grayson, et al. 2022. “Mepolizumab Decreases Tissue Eosinophils While Increasing Type‐2 Cytokines in Eosinophilic Chronic Rhinosinusitis.” Clinical & Experimental Allergy 52 (12): 1403–13. doi:10.1111/cea.14152.